(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

SEQIRUS

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: CombinedOffice: United States

Quick snapshot

SEQIRUS

ST13

US500000086727032

Class

1, 5, 44

Filing

86727032

Registration

5184313

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

47

Latest update

04/19/2026

Trademark type

Combined

Nice classes

1, 5, 44

Filing date

08/17/2015

Registration date

04/18/2017

Expiration date

-

Complete case details

Structured fields from the responsible authority and the official record.

Status date

04/16/2024

Last transaction

04/19/2026

Responsible office

United States Patent and Trademark Office

Status code

705

Official register

Principal Register

Filing basis

Intent to use, Foreign priority

Drawing code

3

Owner type

99

Owner location

Berkshire, GB

Examiner

SNABB, SANDRA MARIE

Law office

N20

Mark description

The mark consists of stylized wording "SEQIRUS" with a curved line over the letter "S" under another curved line which spans from over the letter "S" to over the letter "E".

Holders and representatives

Holders

Seqirus UK Limited
Seqirus UK Limited

Representatives

Nancy Sabarra Fross Zelnick Lehrman & Zissu, P.C.

Technical classification

Nice Classes

Class 1Class 5Class 44

Vienna Codes

No Vienna codes available.

Goods and services

Class 1

Chemical and biological reagents for scientific and non-medical purposes; cell cultures and media for laboratoryscientific and research use; test kits for scientific and non-medical laboratory use for anti-body screeningblood grouping or detection of specific blood cellsantigens and immunoglobulin subtypes; chemical preparations for scientific and industrial purposes; diagnostic and testing agents for scientific and non-medical purposes; Chemical and biological reagents for non-medical purposes; chemical and biological reagents for industrial use for anti-body screeningblood groupingfor the typing and detection of specific blood cellsdetermining the presence of antigens on blood cellsthe detection of relevant complement compounds and immunoglobulin subtypes; chemical test kits for the detection of specific blood cellsdetermining the presence of antigens on blood cellsthe detection of relevant complement compounds and immunoglobulin subtypes for laboratory or research use; chemical preparations for industrial use for anti-body screeningblood groupingthe typing and detection of specific blood cells

Class 5

Pharmaceutical preparations and substances for the treatment and prevention of blood disordersbleeding disordersdiseases caused by bacteria and viruses; vaccines; blood productsimmunoglobulins for medical or clinical use; medicated serums for the treatment of influenza; anti-virals; influenza vaccines; adjuvants and antigens for medical purposes; blood productsblood plasmareagent blood cells; products derived from blood and products derived from recombinant DNA technologyimmunoglobulinshuman albuminblood clotting factorsplasma volume expandersblood proteins for therapeutic use; serumsanti-venoms; medicated serums for the treatment of blood disorders and bleeding disorders; test kitsinvitro diagnostic reagent test kits for use in detecting cell mediated immune response; pharmaceutical preparations and substancesRheysys Factor D Antigen reagents for the detection of specific antigens or in blood typing; pharmaceutical preparationsreagent red blood cells used to detect antibodies and Immunoglobulin subtypes; pharmaceutical preparationstherapeutic monoclonal and polyclonal antibodies and antibodies for use in the treatment of infectious diseases ; pharmaceutical preparationsreagents for medical and clinical use for the typing and detection of specific blood cellsthe detection of relevant compliment components and immunoglobulin subtypes

Class 44

Medical services; medical information services; health care services; health care information servicesinternet-based health care information services; providing medical information concerning blood products; providing medical information concerning vaccinesanti-venoms and immunohematology productsdiagnostic reagents; patient support servicesproviding an Internet-based database of patient medical informationwhere patients can enquire about medical issues and procedures from other patients and can relay information about their medical experiences for support and community

Publications

History of USPTO decisions and trademark events.

47 publications found

REM2

COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED

04/18/2026

NA85

NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED

04/16/2024

C15P

REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.

04/16/2024

APRE

CASE ASSIGNED TO POST REGISTRATION PARALEGAL

04/16/2024

E815

TEAS SECTION 8 & 15 RECEIVED

10/18/2023

REM1

COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED

04/18/2022

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

11/25/2019

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

11/25/2019

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

12/18/2018

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

12/18/2018

R.PR

REGISTERED-PRINCIPAL REGISTER

04/18/2017

DP1B

1(B) BASIS DELETED; PROCEED TO REGISTRATION

03/13/2017

AITU

CASE ASSIGNED TO INTENT TO USE PARALEGAL

03/13/2017

IUCN

NOTICE OF ALLOWANCE CANCELLED

03/06/2017

D1BR

TEAS DELETE 1(B) BASIS RECEIVED

03/06/2017

NOAM

NOA E-MAILED - SOU REQUIRED FROM APPLICANT

02/07/2017

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

12/13/2016

PUBO

PUBLISHED FOR OPPOSITION

12/13/2016

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

11/23/2016

PREV

LAW OFFICE PUBLICATION REVIEW COMPLETED

11/10/2016

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

11/03/2016

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

10/31/2016

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

10/31/2016

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

10/24/2016

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

09/20/2016

GNRT

NON-FINAL ACTION E-MAILED

09/20/2016

CNRT

NON-FINAL ACTION WRITTEN

09/20/2016

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

09/01/2016

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

09/01/2016

ALIE

ASSIGNED TO LIE

08/25/2016

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

08/18/2016

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

07/01/2016

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

07/01/2016

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

06/24/2016

GNRT

NON-FINAL ACTION E-MAILED

06/24/2016

CNRT

NON-FINAL ACTION WRITTEN

06/24/2016

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

06/03/2016

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

06/02/2016

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

06/02/2016

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

06/02/2016

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

12/03/2015

GNRT

NON-FINAL ACTION E-MAILED

12/03/2015

CNRT

NON-FINAL ACTION WRITTEN

12/03/2015

DOCK

ASSIGNED TO EXAMINER

12/01/2015

MDSC

NOTICE OF DESIGN SEARCH CODE E-MAILED

08/21/2015

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

08/20/2015

NWAP

NEW APPLICATION ENTERED

08/20/2015

Continuous trademark protection

Get notified about every new filing that threatens SEQIRUS or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.